Evaluation of COVID-19 antibody therapies

IRF参与开发检测和半定量SARS-CoV-2中和抗体的分析方法，作为可能的治疗方法。病原体特异性抗体的鉴定以及用于繁殖和纯化它们的技术的进展已经允许开发抗体作为潜在的治疗剂，同时降低并发症的可能性。IRF一直与多个合作者合作，在体外中和和总抗体测定以及COVID-19仓鼠模型中评估候选抗体以及恢复期血浆。

The IRF has engaged in development of assays for detection and semi-quantification of neutralizing antibodies to SARS-CoV-2 as possible therapeutics. Advances in identification of pathogen specific antibodies and techniques for propagating and purifying them has allowed development of antibodies as potential therapeutics with reduced possibility of complications. The IRF has been working with multiple collaborators to evaluate antibody candidates as well as convalescent plasma in in-vitro neutralizing and total antibody assays and the hamster model of COVID-19.